The EFHD1 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the EFHD1 gene has been disrupted in the Jurkat human T lymphocyte line. This loss-of-function model enables the study of EFHD1-dependent signaling and cellular processes without introducing monoclonal artifacts. The polyclonal format preserves population-level heterogeneity, providing a robust tool for investigating the functional consequences of EFHD1 ablation in T-cell biology.
The parental Jurkat cell line is an immortalized T lymphocyte model derived from the peripheral blood of a 14-year-old male with acute T cell leukemia. Originating from CD4+ T cells, Jurkat cells are widely employed as a model system for T-cell receptor (TCR) signaling, activation, and apoptosis. Their well-characterized signaling network and responsiveness to TCR/CD3 stimulation make them an ideal host for dissecting the roles of calcium-binding proteins such as EFHD1 in immune cell function and leukemogenesis.
EFHD1 is a calcium-binding protein that orchestrates TCR signal transduction, apoptosis, and actin cytoskeletal dynamics. Activated downstream of TCR/CD3 stimulation and CD28 co-stimulation, it is regulated by calcium influx, PKC, and NFAT. EFHD1 interacts with TRAF2, GRB2, and LCK, and binds calcium and phospholipids. It controls downstream effectors including NFAT, NF-??B, AP-1, and caspases, and influences actin reorganization. Mechanistically, it functions within the TCR signaling cascade involving ZAP70, LAT, PLC??1, and IP3-mediated calcium release, leading to calcineurin activation and NFAT dephosphorylation, which govern T-cell activation and survival gene expression.
In Jurkat T cells, disruption of EFHD1 expression impairs calcium flux, attenuates TCR-mediated activation, and alters apoptotic responses, making this knockout model particularly valuable for examining the intersection of calcium signaling, immune activation, and cell death. The EFHD1-deficient Jurkat cells serve as a platform to investigate how aberrant EFHD1 function contributes to T-cell dysregulation in immunodeficiency, autoimmune disorders, and T-cell malignancies. By comparing polyclonal knockout populations with wild-type controls, researchers can dissect the EFHD1-dependent molecular mechanisms that govern T-cell fate decisions, offering insights into leukemogenesis and potential therapeutic targets.
This product is optimally suited for advanced research applications, including T-cell activation studies using flow cytometry for CD69 and CD25, calcium flux assays, and Annexin V apoptosis assays. The polyclonal knockout cells enable co-immunoprecipitation of protein interactions and western blotting for NFAT and NF-??B activation. They are also valuable for proliferation assays and drug sensitivity screens to assess leukemic cell growth and therapeutic responses. For further technical details, please contact Ascent Research.
